Hangzhou Junrui Biotechnology

Junrui Biotech is a China-based biopharmaceutical company specializing in the discovery and development of targeted protein degradation (TPD) therapies. The company focuses on leveraging its proprietary platform to design molecular glues and PROTACs aimed at previously "undruggable" targets in oncology and immunology. Founded in 2021 by industry veterans, Junrui integrates structural biology, computational chemistry, and high-throughput screening to optimize its drug candidates. The company is backed by prominent venture capital firms, including Qiming Venture Partners and Lilly Asia Ventures. Junrui's pipeline is currently in the pre-clinical stage, with multiple programs targeting high-value disease-associated proteins.